OPKO Health Inc. (OPK)

OPKO Health and Entera Bio are partnering to develop a once-daily pill for patients with obesity and other disorders, the companies said on Monday.

LH inks new agreement to acquire BioReference Health's oncology and related clinical testing services businesses.

The strength in OPKO Health's transfer of intellectual property and other revenues boosts its overall fourth-quarter 2024 performance despite lower RAYALDEE sales.

While the top- and bottom-line numbers for OPKO Health (OPK) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics com...

OPKO Health (OPK) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.11 per share. This compares to loss of $0.09 per share a year ago.

OPKO Health, Inc. (NASDAQ:OPK ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Yvonne Briggs - Alliance Advisors IR Dr. Phillip Frost - Chairman and CEO Dr. Elias Z...

Evaluate the expected performance of OPKO Health (OPK) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metr...

OPK's growth is fueled by Rayaldee's success and accelerated clinical trials. However, stiff competition and overdependence on its lead product are concerns.

OPK aims to advance a novel vaccine candidate for EBV infection, provide protective immunity to patients and prevent these diseases.

Insider activity is hot in names like Vestis NYSE: VSTS, OPKO Health NASDAQ: OPK, and Greif, Inc. NYSE: GEF, and investors should take notice. From board members to CEOs, CFOs, and other corporate off...